212 related articles for article (PubMed ID: 31821176)
1. Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors.
Ackeifi C; Swartz E; Kumar K; Liu H; Chalada S; Karakose E; Scott DK; Garcia-Ocaña A; Sanchez R; DeVita RJ; Stewart AF; Wang P
JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31821176
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.
Kumar K; Wang P; Wilson J; Zlatanic V; Berrouet C; Khamrui S; Secor C; Swartz EA; Lazarus M; Sanchez R; Stewart AF; Garcia-Ocana A; DeVita RJ
J Med Chem; 2020 Mar; 63(6):2986-3003. PubMed ID: 32003560
[TBL] [Abstract][Full Text] [Related]
3. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
Adayev T; Wegiel J; Hwang YW
Arch Biochem Biophys; 2011 Mar; 507(2):212-8. PubMed ID: 21185805
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
5. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
[TBL] [Abstract][Full Text] [Related]
6. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication.
Wang P; Alvarez-Perez JC; Felsenfeld DP; Liu H; Sivendran S; Bender A; Kumar A; Sanchez R; Scott DK; Garcia-Ocaña A; Stewart AF
Nat Med; 2015 Apr; 21(4):383-8. PubMed ID: 25751815
[TBL] [Abstract][Full Text] [Related]
7. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
Göckler N; Jofre G; Papadopoulos C; Soppa U; Tejedor FJ; Becker W
FEBS J; 2009 Nov; 276(21):6324-37. PubMed ID: 19796173
[TBL] [Abstract][Full Text] [Related]
8. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.
Kumar K; Wang P; Sanchez R; Swartz EA; Stewart AF; DeVita RJ
J Med Chem; 2018 Sep; 61(17):7687-7699. PubMed ID: 30059217
[TBL] [Abstract][Full Text] [Related]
9. Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells.
Wang P; Karakose E; Liu H; Swartz E; Ackeifi C; Zlatanic V; Wilson J; González BJ; Bender A; Takane KK; Ye L; Harb G; Pagliuca F; Homann D; Egli D; Argmann C; Scott DK; Garcia-Ocaña A; Stewart AF
Cell Metab; 2019 Mar; 29(3):638-652.e5. PubMed ID: 30581122
[TBL] [Abstract][Full Text] [Related]
10. Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
Yoon HR; Balupuri A; Choi KE; Kang NS
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957634
[TBL] [Abstract][Full Text] [Related]
11. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
[TBL] [Abstract][Full Text] [Related]
12. DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis.
Barzowska A; Pucelik B; Pustelny K; Matsuda A; Martyniak A; Stępniewski J; Maksymiuk A; Dawidowski M; Rothweiler U; Dulak J; Dubin G; Czarna A
Cells; 2021 Aug; 10(9):. PubMed ID: 34571911
[TBL] [Abstract][Full Text] [Related]
13. Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System.
Huizar FJ; Hill HM; Bacher EP; Eckert KE; Gulotty EM; Rodriguez KX; Tucker ZD; Banerjee M; Liu H; Wiest O; Zartman J; Ashfeld BL
ChemMedChem; 2022 Feb; 17(4):e202100512. PubMed ID: 34994084
[TBL] [Abstract][Full Text] [Related]
14. CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition.
Abdolazimi Y; Zhao Z; Lee S; Xu H; Allegretti P; Horton TM; Yeh B; Moeller HP; Nichols RJ; McCutcheon D; Shalizi A; Smith M; Armstrong NA; Annes JP
Endocrinology; 2018 Sep; 159(9):3143-3157. PubMed ID: 29514186
[TBL] [Abstract][Full Text] [Related]
15. DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes.
Kumar K; Suebsuwong C; Wang P; Garcia-Ocana A; Stewart AF; DeVita RJ
J Med Chem; 2021 Mar; 64(6):2901-2922. PubMed ID: 33682417
[TBL] [Abstract][Full Text] [Related]
16. Nonprimed and DYRK1A-primed GSK3 beta-phosphorylation sites on MAP1B regulate microtubule dynamics in growing axons.
Scales TM; Lin S; Kraus M; Goold RG; Gordon-Weeks PR
J Cell Sci; 2009 Jul; 122(Pt 14):2424-35. PubMed ID: 19549690
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of DYRK1A and GSK3B induces human β-cell proliferation.
Shen W; Taylor B; Jin Q; Nguyen-Tran V; Meeusen S; Zhang YQ; Kamireddy A; Swafford A; Powers AF; Walker J; Lamb J; Bursalaya B; DiDonato M; Harb G; Qiu M; Filippi CM; Deaton L; Turk CN; Suarez-Pinzon WL; Liu Y; Hao X; Mo T; Yan S; Li J; Herman AE; Hering BJ; Wu T; Martin Seidel H; McNamara P; Glynne R; Laffitte B
Nat Commun; 2015 Oct; 6():8372. PubMed ID: 26496802
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of DYRK1A Stimulates Human β-Cell Proliferation.
Dirice E; Walpita D; Vetere A; Meier BC; Kahraman S; Hu J; Dančík V; Burns SM; Gilbert TJ; Olson DE; Clemons PA; Kulkarni RN; Wagner BK
Diabetes; 2016 Jun; 65(6):1660-71. PubMed ID: 26953159
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration.
Ackeifi C; Wang P; Karakose E; Manning Fox JE; González BJ; Liu H; Wilson J; Swartz E; Berrouet C; Li Y; Kumar K; MacDonald PE; Sanchez R; Thorens B; DeVita R; Homann D; Egli D; Scott DK; Garcia-Ocaña A; Stewart AF
Sci Transl Med; 2020 Feb; 12(530):. PubMed ID: 32051230
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) exert a strong anti-herpesviral activity.
Hutterer C; Milbradt J; Hamilton S; Zaja M; Leban J; Henry C; Vitt D; Steingruber M; Sonntag E; Zeitträger I; Bahsi H; Stamminger T; Rawlinson W; Strobl S; Marschall M
Antiviral Res; 2017 Jul; 143():113-121. PubMed ID: 28400201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
